An Anti-CD4 (CDR3-Loop) Monoclonal Antibody Inhibits Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Induced Apoptosis  by Guillerm, Claire et al.
An Anti-CD4 (CDR3-Loop) Monoclonal Antibody Inhibits Human Immunodeficiency
Virus Type 1 Envelope Glycoprotein-Induced Apoptosis
Claire Guillerm,* Ve´ronique Robert-Hebmann,* Urszula Hibner,† Michel Hirn,‡ and Christian Devaux*,1
*CRBM/CNRS UPR 1086, Laboratoire Infections Re´trovirales et Signalisation Cellulaire, Institut de Biologie, 4 Boulevard Henri IV,
34060 Montpellier Cedex, France; †CNRS UMR 5535, Institut de Ge´ne´tique Mole´culaire de Montpellier,
34033 Montpellier Cedex 1, France; and ‡Immunotech-Coulter, 13009 Marseille, France
Received March 11, 1998; returned to author for revision April 24, 1998; accepted May 26, 1998
Inhibition of human immunodeficiency virus type 1 (HIV-1)-inducing programmed cell death (PCD) by anti-CD4 monoclonal
antibodies (mAbs) was investigated using DNA intercalant YOPRO-1 assay. We found that 13B8.2, an mAb that binds the
CDR3-like loop in domain 1 (D1) of CD4, protected infected CEM cell cultures against HIV-1-induced PCD. Protection was not
observed using another anti-CD4 mAb (BL4) that binds D1-D2, suggesting that the mechanism involved in cell protection
against HIV-1-induced PCD requires engagement of precise CD4 epitopes. Because 13B8.2 is known to inhibit syncytia
formation and virus transcription, this mAb could inhibit HIV-1-induced PCD by (1) inhibiting virus gene expression, (2)
preventing viral envelope-CD4 interaction, and/or (3) interfering with apoptotic signals. Our data indicated that the absence
of enhanced PCD in infected cell cultures treated with 13B8.2 mAb probably was the result of inhibition of HIV-1 replication
and virus spread. Moreover, 13B8.2 mAb was found to inhibit PCD mediated by membrane-expressed HIV-1 envelope
glycoproteins. Finally, we found that 13B8.2 mAb displayed no protective interference with apoptotic signal induced by Fas,
dexamethasone, and serum withdrawal. © 1998 Academic Press
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INTRODUCTION
The human immunodeficiency virus type 1(HIV-1) is
the etiological agent of acquired immune deficiency syn-
drome (AIDS). One of the major characteristics of AIDS is
the gradual depletion of CD41 T lymphocytes during the
development of the disease (Rosenberg and Fauci,1991).
Several mechanisms have been proposed to be respon-
sible for the CD4 cell depletion (Ameisen and Capron,
1991; Laurent-Crawford et al., 1991; Terai et al., 1991;
Hovanessian, 1994). Besides destruction of infected cells
by HIV-specific cytotoxic lymphocytes (CTLs) and anti-
body-dependent cellular cytotoxicity (ADCC), these
mechanisms include the cytopathic effects (CPE) result-
ing from the infection of CD41 T cells by HIV-1. CPE may
be ascribed to HIV-1 envelope glycoprotein 120 (gp120)-
induced generation of syncytia, resulting from cell-to-cell
transmission of the virus and single-cell killing by induc-
tion of programmed cell death (PCD) or apoptosis. Mech-
anisms involved in HIV-1-induced PCD are not fully un-
derstood. PCD can be triggered directly in infected cells
by the virus replication, presumably reflecting host de-
fense mechanisms against virus replication, spread, or
persistence (Ameisen, 1994; Shen and Shenk, 1995).
However, PCD also may be mediated indirectly through
priming of uninfected bystander cells to apoptosis by
gp120. Experiments aimed at defining the molecular
mechanisms involved in HIV-1-induced PCD suggest that
it requires viral transcription and cell surface expression
of gp120 (Laurent-Crawford et al., 1993; Corbeil and Rich-
man, 1995).
An important goal of HIV research is the identification
of molecules inhibitory of HIV-1-induced PCD. During the
search for such molecules, anti-CD4 mAb have been
reported to inhibit HIV-1-induced PCD (Laurent-Crawford
et al., 1993; Hovanessian, 1994; Corbeil and Richman,
1995). However, little is known about the implication of
different CD4 epitopes or about the mechanisms by
which anti-CD4 mAb that bind outside of the gp120-
binding site on CD4 protect cells from apoptosis. In
contrast, a large body of data are available concerning
the inhibition of the HIV-1 life cycle by anti-CD4 mAb. As
a function of the recognized epitope, anti-CD4 mAb will
inhibit (1) HIV-1 binding (e.g., anti-CD4 mAb specific for
the CDR2-loop in domain 1 of CD4) (Dalgleish et al.,
1984; Klatzman et al., 1984); (2) fusion, which is likely to
require conformational changes in CD4 (Moore et al.,
1992); (3) viral transcription, which is controlled by the
state of activation of the infected cell (e.g., anti-CD4 mAb
specific for the CDR3-loop in domain 1 of CD4) (Ben-
kirane et al., 1993, 1995a); or (4) syncytia formation (e.g.,
anti-CD4 mAb specific for the CDR2- or CDR3-loop in
domain 1 of CD4) (Corbeau et al., 1993). These different
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effects can be explained by the multiple functions of
CD4: in addition to acting as a high affinity cell surface
receptor for HIV-1 (which binds the CDR2-loop in domain
1 of CD4), CD4 is involved in the postbinding step or
steps of the viral replication cycle (Benkirane et al., 1994),
as well as in the signal transduction machinery of the
cell (Rudd et al., 1988; Veillette et al., 1989). We chose to
focus our attention on mAb specific for the CDR3-like
region in D1 of CD4. We have previously shown that
13B8.2, a CDR3-like loop-specific mAb, does not inhibit
HIV-1 entry into CD41 T cells (Corbeau et al., 1993;
Benkirane et al., 1993) but rather inhibits HIV-1-induced
syncytia formation (Corbeau et al., 1993) and HIV-1 tran-
scription in cells containing an integrated provirus or
proviruses (Benkirane et al., 1993, 1995a). Now we have
set out to test whether the 13B8.2 mAb, acting on HIV-1
gene expression (including env expression), gp120-CD4
binding during cell-to-cell transmission of HIV-1, and cell
signaling, inhibits HIV-1-induced PCD.
We report that the CDR3-like loop-specific anti-CD4
13B8.2 mAb protects infected cell culture against HIV-
1-induced apoptosis, whereas another anti-CD4 mAb
does not.
RESULTS
13B8.2 mAb treatment protects infected cell cultures
against HIV-1-mediated cell death
We studied the ability of two anti-CD4 mAbs, 13B8.2
mAb (which binds to the Ig CDR3-like region of the D1
domain of the CD4 molecule) and BL4 mAb (which binds
an epitope of the D1-D2 domains of CD4), to protect
infected cell cultures against HIV-1-induced cell death.
CEM cells were exposed to HIV-1 at 1,0003 tissue cul-
ture infectious dose50 (TCID50)/ml and then cultured in
either medium alone or medium supplemented with
13B8.2 mAb or with BL4 mAb at a concentration fourfold
greater than necessary for saturation of cell surface
CD4. The percentage of dead cells in the culture was
estimated by trypan blue exclusion, whereas virus pro-
duction was evaluated in cell-free culture supernatants
by RT activity assay performed twice a week during 2
weeks. HIV-1-induced apoptosis was measured using
specific cell staining with the DNA intercalant dye YO-
PRO-1. As shown in Figure 1, significant numbers of dead
cells appeared in cultures ;3 days after virus production
could be detected in culture supernatants of HIV-1-in-
fected cells. The percentage of dead cells in cultures of
cells grown in medium alone or in medium supple-
mented with the BL4 mAb reached a plateau of ;40% on
day 6 and day 9 postinfection, respectively. In contrast,
the percentage of dead cells in cultures grown in the
presence of 13B8.2 mAb was very low and indistinguish-
able from uninfected CEM cells over 14 days of culture.
In agreement with data previously reported by our labo-
ratory (Benkirane et al., 1993, 1995a), viral particles were
detected in culture supernatants of HIV-1-infected cells
grown in medium alone or in medium supplemented with
the BL4 mAb, whereas a treatment with the 13B8.2 mAb
prevented HIV-1 particle production (Fig.1-B). Moreover,
13B8.2 mAb treatment did not decrease cell proliferation
according to our biweekly total cell counts (data not
shown; Pe´le´raux et al., 1998).
Although 13B8.2 mAb-treated cells were infected by
HIV-1, as demonstrated by polymerase chain reaction (PCR)
analysis of HIV-1 DNA performed 24 h after virus exposure
(Fig. 1C), 13B8.2 mAb-mediated protection against HIV-1-
induced cell death was observed during the 14 days of
culture. The percentage of apoptotic cells in HIV-1-infected
cells cultured in medium alone or medium supplemented
FIG. 1. Effect of anti-CD4 mAb treatment on cell viability and virus
production in HIV-1 infected cell cultures. Cells were exposed to 100 ml
of virus suspension containing 1000 3 TCID50/ml HIV-1LAI, washed,
and cultured in medium alone (r) or in medium supplemented with
anti-CD4 mAb 13B8.2 () or with anti-CD4 mAb BL4 (F) at a concen-
tration fourfold greater than necessary for saturation of cell surface
antigens. Uninfected cells are shown as control (M). (A) Viability was
evaluated by trypan blue exclusion. (B) Viral production was monitored
by measuring reverse transcriptase activity. A representive experiment
of four is shown. (C) HIV-1 DNA was monitored by PCR analysis
(M667/GAG2 oligonucleotide primer pair) performed on total DNA ex-
tracted from CEM cells infected with HIV-1 (lane 2) or CEM cells
infected with HIV-1 and treated with anti-CD4 mAb 13B8.2 (lane 3) or
BL4 (lane 4) 24 h after virus exposure. Lane 1 represents virus-free
CEM cells. Products of PCR amplification using b-globinI/b-globin II
oligonucleotide primer pair hybridized to an a-32P-labeled b-globin
probe are shown as control. (D) The percentage of apoptotic cells in
cell cultures was monitored at days 3, 7, and 14 of culture by flow
cytometry analysis using the impermeant DNA intercalant YOPRO-1.
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with anti-CD4 mAb was assessed by flow cytometry anal-
ysis on days 3, 7, and 14 postinfection. As shown in Figure
1D, staining by the YOPRO-1 was observed in HIV-1-in-
fected cells cultured in absence of mAb or in the presence
of BL4 mAb at 7 days postinfection. After 14 days of culture,
most of the cells (72.6% in the culture maintained in me-
dium alone and 51.8% for the culture performed in the
presence of BL4) were stained by the YOPRO-1, indicating
a major phenomenon of apoptotic cell death. In the unin-
fected control culture, 16.4% of cells were stained by YO-
PRO-1, whereas under the same experimental conditions,
26.2% of cells treated by 13B8.2 mAb were stained by the
YOPRO-1. Thus, 13B8.2 mAb protected cells against HIV-1-
induced apoptotic cell death. Similar results were obtained
when 13B8.2 mAb was added to cultures of CEM cells 6 h
postinfection (Fig. 2). Under these experimental conditions
(in which the early stages of virus replication cycle have
occurred), 13B8.2 mAb still protected infected cultures from
HIV-1-induced apoptosis (5.7% of cells were stained with
YOPRO-1 compared with 29.6% in the control culture). This
protective effect of 13B8.2 mAb was confirmed using an-
other assay that consisted of the observation of nucleus
condensation and apoptotic bodies formation under fluo-
rescence microscopy after Hoechst nuclear staining (C.G.,
unpublished observations).
Thus, there was no enhanced cell death in cell
cultures treated by the Ig CDR3-like loop-specific
13B8.2 mAb, even though these cells were infected by
HIV-1. In contrast, an anti-CD4 mAb directed against a
different epitope did not protect cells against HIV-1
infection-associated cell death. However, it should be
pointed out that 24 h after virus exposure, the number
of infected cells should be low (;100/5 3 105 cells)
and virus spread in cell culture should be inhibited by
13B8.2 mAb, which is a known inhibitor of HIV-1 tran-
scription (Benkirane et al., 1993, 1995a), whereas virus
spreading occurs in control cultures. Indeed, we re-
ported previously that the amount of viral DNA 7 days
after virus exposure was lower in infected CD4 T-cells
treated with 13B8.2 mAb than in infected control cell
cultures (Briant et al., 1996a).
Combined, these data indicate that apoptosis of HIV-1
infected cells was not observed when the cells were
cultured inmedium containing the Ig CDR3-like loop-
specific 13B8.2 mAb, but probably 13B8.2 mAb-mediated
inhibition of HIV-1-induced apoptosis resulted from inhi-
bition of HIV-1 transcription leading to inhibition of virus
spread.
Cell surface-expressed HIV-1 envelope glycoprotein-
induced apoptosis is inhibited by 13B8.2 mAb
treatment
HIV-1-induced apoptosis is generally thought to re-
quire both viral replication and engagement of ex-
pressed gp120 with CD4 molecules (Laurent-Crawford,
1993; Corbeil and Richman, 1995). However, membrane-
expression of HIV envelope glycoproteins can also trig-
ger apoptosis in CD41 cells (Maldarelli et al., 1995).
Although the molecular mechanism by which cell sur-
face-expressed gp120 triggers apoptosis in CD41 cells
is not understood, we designed experiments that were
aimed at reproducing this phenomenon and were useful
in testing the ability of 13B8.2 mAb to inhibit this process.
We used control human embryonic kidney (HEK) 293
cells and HEK 293 cells transiently transfected by a
vector pBRUDgag, which allows HIV-1 LAI env gene ex-
pression in the absence of an HIV-1 infection (these cells
are hereafter referred to as HEK 293/gp120) to check
whether cell surface-expressed HIV-1 envelope glyco-
protein can trigger apoptosis in CD4-positive CEM cells
during cocultures. As shown in Figure 3-A, HEK 293 cells
transiently transfected with pBRUDgag, but not the pa-
rental HEK 293 cells, were found to express gp120. As
shown in Figure 3B, 31.3% of CEM cells underwent apop-
tosis in cocultures with HEK 293/gp120 cells, whereas
only 7.15% of CEM cells died in cocultures with control
HEK 293 cells, indicating that gp120 expressed at the
FIG. 2. Effect of 13B8.2 mAb-treatment on HIV-1-induced apoptosis. Cells exposed to HIV-1LAI (see legend of Fig. 1 for details) were cultured in
medium alone (CEM-HIV) or in medium supplemented with anti-CD4 mAb 13B8.2 immediately after virus exposure (CEM-HIV113B8.2) or 6 h after
virus exposure (CEM-HIV113B8.2 6 h). The percentage of apoptotic cells in cell cultures was assessed at day 9 of culture by flow cytometry analysis
using YOPRO-1.
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FIG. 3. Effect of coculture between HIV-1 env-expressing cells and CEM cells on apoptosis of CEM cells. (A) Expression of HIV-1 envelope
glycoprotein at the surface of HEK 293/gp120 cells was assessed by indirect flow cytometry analysis using the anti-gp120 mAb 110.4 and a
fluoresceinated GAM probe. The reactivity with untransfected HEK 293 cells is shown as control. (B) HEK 293 or HEK 293/gp120 cells were cocultured
with CEM cells either in the absence of mAb (No) or the presence of anti-CD4 mAb (13B8.2 and BL4) or anti-CD45 mAb (9.4). After 3 days of incubation,
the nonadherent CEM cells were harvested (the samples contained .99% CD45-positive CEM cells), and the percentage of apoptotic CEM cells in
culture was assessed by flow cytometry analysis using YOPRO-1. The results are shown as mean values from triplicate assays (standard deviation
is indicated). (C)Photomicrographs illustrating light microscopic observations (magnification, 400-fold for top and 200-fold for bottom) of HEK
293/gp120 adherent cells cocultured with nonadherent (CEM cells for 3 days in the absence of mAb (No additive) or the presence of anti-CD4 mAb
(13B8.2). Dead cells were visualized by trypan blue uptake. The difference in color of the pictures (pink in the HIV-1-infected control cell culture and
yellow in 13B8.2 mAb-treated culture) reflects the difference in pH of the culture medium, which varies depending on cell proliferation and indicates
that 13B8.2 mAb does not appear to have a cytostatic effect.
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surface of HEK 293/gp120 cells triggers apoptosis. HEK
293/gp120 cell-induced CEM apoptosis was inhibited by
an anti-HIV-1 gp120 V3-loop-specific antibody (C.G., un-
published observations).
Next, we investigated whether 13B8.2 mAb can inhibit
cell surface-expressed HIV-1 envelope glycoprotein-in-
duced apoptosis. The percentage of dead cells in un-
treated cocultures of HEK 293/gp120 with CEM cells was
much higher than that in coculture of cells maintained in
medium containing 13B8.2 mAb (Fig. 3C). Under the
same experimental conditions, when the percentage of
apoptotic CEM cells was evaluated by YOPRO-1 assay
performed on nonadherent cells (Fig. 3B), 13B8.2 mAb
was found to inhibit CEM cell apoptosis (14.7% com-
pared with 31.3% in the control sample). In contrast,
neither BL4 anti-CD4 mAb (32.25% apoptosis) nor anti-
CD45 mAb (33.5% apoptosis) inhibited HEK 293/gp120-
induced apoptosis of CEM cells.
Our data corroborate previous observations (Maldarelli
et al., 1995) indicating that gp120 expressed at the surface
of ‘‘stimulating cells’’ induces apoptosis in CD41 ‘‘respond-
ing cells.’’ Because our experiments were performed in a
model of uninfected cells (HEK 293/gp120) that artificially
express gp120, they strongly support the hypothesis of
Corbeil and Richman (1995) that engagement of expressed
gp120 with CD4 molecules contributes to complete the
signalization process in infected cells.
13B8.2 mAb treatment fails to prevent anti-Fas IgM-
induced apoptosis or dexamethasone and serum
withdrawal-induced apoptosis
Since 13B8.2 mAb acts on T cell activation via CD4
(Benkirane et al., 1993, 1995b; Lemasson et al., 1996), it
was tempting to investigate whether this mAb could
inhibit signaling pathways which control apoptosis. Cell
surface Fas (CD95) expression is strongly induced fol-
lowing HIV-1 infection (Badley et al., 1996), and increase
in Fas expression is expected to modify the sensitivity of
T cells for Fas-mediated apoptosis ex-vivo (Katsikis et al.,
1995) and to be related to disease progression and
CD41 T cell depletion in HIV-1 infected patients (Boudet
et al., 1996; Gehri et al., 1995). Therefore, we first focused
our attention on the Fas pathway and investigated the
ability of 13B8.2 mAb to modulate cell surface expression
of CD95. Consistent with data reported in the literature,
we found a slight increase in Fas (UB2 epitope) expres-
sion 10 days after infection of cells by HIV-1, whereas
13B8.2 mAb treatment maintained surface expression of
Fas at a level indistinguishable from that of the unin-
fected cells (C.G., unpublished observations).
Because 13B8.2 mAb inhibits HIV-1-induced upregula-
tion of Fas, this mAb may influence apoptosis induced
through the Fas pathway. Therefore, we next examined
the effect of 13B8.2 mAb treatment on CEM cells apop-
tosis triggered by anti-Fas IgM mAb. Cells were treated
with the CH-11 anti-Fas IgM mAb and then cultured in
medium alone or medium supplemented with 13B8.2 or
BL4 anti-CD4 mAb and stained by the YOPRO-1. As
shown in Figure 4A, apoptosis was induced in cultures of
cells treated with CH-11. In contrast, enhanced apoptosis
FIG. 4. Effect of anti-CD4 mAb treatment on anti-Fas IgM- and
dexamethasone-induced apoptosis. (A) Anti-Fas IgM-induced apopto-
sis. Cells were cultured in medium alone (no additive) or in medium
supplemented with 1 mg/ml anti-Fas IgM mAb (CH-11) or with anti-Fas
IgM mAb and anti-CD4 mAb (13B8.2 or BL4). The percentage of apo-
ptotic cells in cultures was assessed by flow cytometry analysis using
the impermeant DNA intercalant YOPRO-1 at 16 h of culture. Controls
consisted of cells treated with ZB4, an antagonist anti-Fas IgMmAb,
before anti-Fas IgM mAb treatment and of cells treated with an isotype-
matched (IgM) mAb. (B) Dexamethasone (1027 M)-induced apoptosis.
Cells were cultured in medium alone (no additive), in medium supple-
mented with dexamethasone, or in medium supplemented with dexa-
methasone and anti-CD4 mAb. The percentage of apoptotic cells in cell
cultures was measured as in A at day 3 of culture.
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was not observed with an isotype-matched control Ig
and was inhibited by ZB4, an antagonist anti-Fas IgG
mAb, which competes with CH-11 for binding to Fas. The
presence of 13B8.2 or BL4 anti-CD4 mAb in the culture
medium had no significant effect on the observed per-
centage of apoptotic cells.
To verify that 13B8.2 mAb treatment had no general
antiapoptotic effect on the CEM cells, we examined the
induction of apoptosis in CEM cells by dexamethasone
and by serum withdrawal. Figure 4B illustrates a repre-
sentative experiment in which apoptosis was induced by
dexamethasone. Neither 13B8.2 nor BL4 mAb had a
significant effect on CEM cells apoptosis induced by
dexamethasone. Similarly, apoptosis induced by serum
withdrawal was not inhibited by either 13B8.2 or BL4
mAb treatment (data not shown).
Thus, Ig CDR3-like specific 13B8.2 mAb inhibited HIV-
1-induced Fas antigen modulation (probably by inhibiting
HIV-1 transcription) but did not inhibit apoptosis induced
by anti-Fas IgM stimulation, dexamethasone, or serum
withdrawal.
DISCUSSION
CD41 T cells undergo apoptosis when infected by
HIV-1. The aim of the present study was to investigate
whether anti-CD4 mAb can protect infected cell cultures
against HIV-1-induced apoptosis. We show that the treat-
ment of cells with 13B8.2 (a mAb that binds to the CDR3-
like loop in D1 of CD4) within the first 6 h postinfection
protects the CD41lymphoblastoid CEM cells against
HIV-1-induced apoptosis. Moreover, cell surface-ex-
pressed HIV-1 envelope glycoprotein-induced apoptosis
also was inhibited by 13B8.2 mAb treatment. In contrast,
BL4 (another anti-CD4 mAb that binds D1-D2) fails to
protect cells against HIV-1-induced and cell surface-
expressed HIV-1 envelope glycoprotein-induced PCD.
Several viruses, including retroviruses such as human
T-cell leukemia virus type I, counter PCD mechanisms by
encoding proteins that inhibit the cellular apoptotic ma-
chinery (Levine et al., 1993; Henderson et al., 1993; Chiou
et al., 1994; Yamada et al., 1994; Gillet et al., 1995; Afon-
son et al., 1996). In contrast, HIV-1 is an example of a
virus causing a drastic cell depletion by apoptosis (Li et
al., 1995; Purvis et al., 1995; Westendorp, 1995). As ex-
pected, we found here that HIV-1 infection induces a
dramatic PCD in infected cultures. It is worth noting that
virus production begins 3 days before significant PCD
could be detected in the culture. It is generally admitted
that HIV-1 induces activation signals in CD41 cells (Ben-
kirane et al., 1994; Chirmule et al., 1995; Merzouki et al.,
1995; Popik and Pitha, 1996; Briant et al., 1996). Uncon-
trolled and chronic immune activation triggered by HIV-1
is probably the primary mechanism responsible for the
collapse of the immune system observed in AIDS. This
activation process should involve transcription factors
stimulating cell activation and virus replication but also
triggering activation-induced apoptosis. Probably, the ki-
netics of events controlled by the molecular crosstalk
between the virus and the host cell should favor the virus
replication first, whereas HIV-1-induced PCD should oc-
cur at a second stage, once the virus-replicative cycle (at
the level of a single cell) is completed. It is worth noting
that PCD can be induced by HIV-1 in cells expressing
truncated forms of CD4 that lack the cytoplasmic domain
(Jacotot et al., 1997; Guillerm et al., 1998), suggesting that
delivery of the apoptotic signals probably involves a
signal transduction molecule other than CD4. One hy-
pothesis is that the HIV-1 coreceptor CXCR4 maybe im-
plicated in HIV-1-induced PCD.
Several anti-CD4 mAbs (OKT4A and Leu3a, which
block gp120 binding to CD4 and inhibit syncytia forma-
tion, and OKT4, which demonstrates no ability to inhibit
gp120-CD4 interactions), prevent HIV-1-induced PCD
when added to the cell culture medium postinfection
(Laurent-Crawford et al., 1993; Hovanessian, 1994; Cor-
beil and Richman, 1995). However, the mechanism by
which these mAbs inhibit PCD remains largely unknown.
The possibility of rescuing HIV-1-infected cells from PCD
by two other anti-CD4 mAbs (13B8.2 and BL4), as well as
the possible mechanisms controlling resistance to PCD,
were investigated in this study. We found that a treatment
of infected cells with 13B8.2 protects the CD41 lympho-
blastoid CEM cells against HIV-1-induced apoptosis,
whereas BL4 shows no such protective effect. We then
investigated the mechanisms by which the 13B8.2 mAb
protects infected cell cultures from HIV-1-induced apop-
tosis. One could hypothesize that 13B8.2 inhibits HIV-1-
induced PCD by (1) inhibiting virus gene expression, (2)
preventing viral envelope-CD4 interaction, and/or (3) in-
terfering with apoptotic signals.
First, we investigated whether 13B8.2 mAb protects
infected cells from HIV-1-induced PCD and whether pro-
tection results from inhibition of virus gene expression.
Indeed, virus gene expression requires cell activation
and nuclear translocation of cellular transcription factors
acting on the viral promoter. The association of cell
activation with apoptosis has been reported in several
viral infections. Increased susceptibility to apoptosis of
peripheral lymphocytes from an HIV-infected person cor-
relates with an activated phenotype (CD41, HLA-DR1,
CD381, CD45RO1, Fas1) (Gougeon et al., 1996). In
agreement with previous reports (Benkirane et al., 1994;
Borvak et al., 1995; Chirmule et al., 1995; Merzouki et al.,
1995; Schmid-Antomarchi et al., 1996), we demonstrated
that binding of uninfectious HIV-1 (inactivated by heating
at 56°C) or gp120-anti-gp120 immune complexes to CD4
molecules of infected resting peripheral blood mononu-
clear cells was sufficient to activate NF-kB and AP-1
DNA-binding proteins to induce a transition from the
G0/G1 to S/G2/M stages of the cell cycle, to trigger the
cell surface expression of the CD25 activation marker, to
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stimulate provirus integration, and to commit cells to
virus production (Briant et al., 1996b). We have also
previously shown that 13B8.2 mAb blocks activation of
MAP kinase (Benkirane et al., 1995b) and NF-kB (Lemas-
son et al., 1996) induced by HIV-1 binding to CD4 and
inhibits HIV-1 transcription (Benkirane et al., 1993, 1995a;
Benkirane et al., 1995b; Lemasson et al., 1996; Coudron-
nie`re et al., 1998). These results corroborate the obser-
vation by Jabado et al. (1994) indicating that 13B8.2 mAb
inhibits NF-kB activation of interleukin-2 promoter in-
duced by an anti-CD3 mAb plus a protein kinase C
activator. Therefore, the mechanism of action of 13B8.2
mAb could correspond, at least in part, to the inhibition of
nuclear translocation of NF-kB and the ensuing lack of
HIV-1 promoter activation. In our experiments, inhibition
of virus gene expression probably accounts for an inhi-
bition of virus spread to uninfected cells, and apoptosis
is not induced in the presence of 13B8.2 mAb as the
majority of cells are not infected. Moreover, a direct
consequence of transcriptional inhibition by 13B8.2 mAb
is the lack of gp120 expression at the surface of infected
cells. Under these conditions, the mechanism of induc-
tion of apoptosis by cell surface-expressed gp120 is
inoperative.
Second, we studied whether 13B8.2 mAb, which is
known to inhibit HIV-1-mediated syncytia formation (Cor-
beau et al., 1993), blocks HIV-1-induced apoptosis by
preventing viral envelope (expressed at the cell surface)
to interact with CD4. We found that HEK 293 cells ex-
pressing the HIV-1 envelope glycoprotein trigger CEM
cell apoptosis during coculture experiments. Moreover,
we demonstrated that 13B8.2 mAb inhibited apoptosis of
CEM cells cocultured with HEK293/gp120 cells. This
result supports the hypothesis that a direct contact be-
tween cell surface gp120 and CD41 cells initiates PCD in
the CD41 population. Obviously, this result does not
exclude the possibility that HIV-1-induced PCD involves
a signal transduction through the HIV-1 coreceptor
CXCR4; indeed there is a possibility that CD4 can indi-
rectly trigger HIV-1-induced PCD by allowing optimal
interactions between the gp120-gp41 and the CD4-
CXCR4 complexes. This hypothesis proposing that a
direct contact between cell surface gp120 and CD41
cells initiates PCD could explain why anti-CD4 mAb
OKT4A and Leu3a prevent HIV-1-induced PCD when
added to the cell culture medium postinfection (Hovan-
essian, 1994; Corbeil and Richman, 1995); although these
mAbs do not act on HIV-1 transcription, they block gp120
binding to CD4. It is worth noting that in contrast to the
results obtained using cell surface-expressed gp120, we
have not observed induction of PCD by incubating CD41
target cells with high concentrations of heat-inactivated
HIV-1 (data not shown). This result is suggestive of a
specific requirement for cell surface expression of gp120
in HIV-1-induced PCD.
Third, interference with apoptotic signals was ana-
lyzed. Survival signals provided by the cell surface pro-
teins CD2 and CD28 have already been reported to
rescue CD41 T cells from HIV-gp120-induced apoptosis
(Tuosto et al., 1995). Because we have shown previously
that 13B8.2 mAb acts on T-cell signaling (Benkirane et al.,
1995b; Lemasson et al., 1996; Coudronnie`re et al., 1998),
the possibility that 13B8.2-mediated protection of cells
against HIV-1-induced PCD involves a complex mecha-
nism of cell signals preventing apoptosis had to be
considered. We found that 13B8.2 mAb does not inhibit
anti-Fas IgM mAb-, dexamethasone-, or serum withdrawal-
induced apoptosis, suggesting that the effect observed
is restricted to HIV-1-induced cell death.
In conclusion, we have shown here that 13B8.2 mAb
treatment protects infected cell cultures against HIV-1-
induced apoptosis. We found that 13B8.2 mAb-mediated
protection against HIV-1-induced PCD parallels inhibi-
tion of HIV-1 transcription and virus replication, suggest-
ing that these events are strongly linked. Moreover,
13B8.2 mAb also acts on PCD of CD41 cells induced by
interaction with cell surface-expressed gp120. Alto-
gether, our results indicate that 13B8.2 mAb treatment
inhibits two major steps of HIV-1-replicative cycle that
contribute to induce apoptosis.
MATERIALS AND METHODS
Monoclonal antibody and reagents
Purified anti-CD4 IOT4A/13B8.2 Ig G1 mAb and IOT4/
BL4 IgG2a mAb were prepared by Immunotech-Coulter
(Marseille, France). Characterization of these anti-CD4
mAbs was reported previously (Corbeau et al., 1993;
Benkirane et al., 1993, 1995a). Anti-CD4 mAbs were used
at a concentration fourfold greater than necessary for
saturation of cell surface CD4, as previously determined
(Corbeau et al., 1993). Anti-Fas (CH-11) IgM mAb, anti-
Fas (ZB4) IgM mAb, and FITC-labeled F (ab9)2 goat anti-
mouse Ig reagent were purchased from Immunotech.
Anti-gp120 (110.4) mAb was provided by Genetic Sys-
tems (Seattle, Washington). Anti-CD45 (9.4) mAb was
provided by American Type Culture Collection (Bethesda,
Maryland). DNA intercalant dye YOPRO-1 was pur-
chased from Molecular Probes (Eugene, Oregon).
Cells and viruses
The CD41 lymphoblastoid CEM cell line was ob-
tained from American Type Culture Collection. Cells
were cultured in RPMI 1640 medium supplemented
with 1% penicillin-streptomycin antibiotic mixture, 1%
Glutamax (Life Technologies, Eragny, France), and 10%
fetal calf serum (Life Technologies) to a density of 5 3
105 cells/ml in a 5% CO2 atmosphere. The HEK 293 cell
line was provided by P. Boulanger (Institut de Biologie,
Montpellier, France). HEK 293/gp120 cells were ob-
tained by transient transfection of HEK 293 cells (using
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the calcium phosphate coprecipitation method) with
the HIV-1 defective pBRUDgag construct, which allows
HIV-1 env gene expression. pBRUDgag derives from
pBRU3 vector (an HIV-1LAI expression vector), kindly
provided by L. Montagnier (Institut Pasteur, Paris,
France), in which the PstI/ApaI gag sequence was
deleted. Viral stocks (HIV-1LAI) were prepared from
chronically infected CEM cell supernatants, as previ-
ously described (Corbeau et al., 1990), and were
treated for 30 min with 100 U of RNase-free DNase/ml.
Assay for HIV-1 infection
Cells (5 3 105) were incubated for 30 min at 4°C in
flat-bottom, 96-microwell plates (Costar, Badhoevedorp,
the Nederlands) with 100 ml of HIV-1 at a concentration of
1,000 3 TCID50/ml. Thereafter, cells were washed five
times and cultured in 24-microwell plates (Costar). The
amount of HIV-1 produced by CEM cells was monitored
twice each week by measuring reverse transcriptase
activity in 1 ml of cell-free culture supernatant using a
synthetic template primer, as previously described (Cor-
beau et al., 1990).
PCR assays
HIV-1-DNA was monitored by PCR according to the
previously described procedure (Benkirane et al., 1993).
Briefly, total DNA was extracted from 1 3 106 cells by
alkaline lysis and resuspended into 200 ml of H2O. The
amplification mixture consisting of 20 mM Tris-HCl, pH
8.3, containing 120 mM concentration of dNTPs, 1.5 mM
MgCl2, 50 mMKCl, 0.005% Tween 20, 0.005% Nonidet
P-40, 0.001% gelatin, 20pmol of each of the oligonucleo-
tide primers M667 and GAG2 (Benkirane et al., 1993), and
2 U of Taq DNA polymerase was added to DNA. The
amplification reaction was run in a PHC2 thermal cycler
(Techne, Cambridge, UK). The amplified products (674-bp
fragments) were analyzed by electrophoresis in a 1%
agarose gel, blotted for 2 h onto Hybond N1 membrane
(Amersham), and hybridized with a-32P-labeled HIV-1
probe. Labeled viral DNA products were visualized by
autoradiography.
Flow cytometry
Cells (1 3 106) were incubated for 60 min at 4°C with
saturating concentrations of anti-gp120 mAb or medium
alone. After washing three times with PBS containing 0.2%
bovine serum albumin, bound mAb was detected by the
addition of 50 ml of a 1:50 dilution of fluoresceinated goat
anti-mouse immunoglobulin (Immunotech). After 60 min of
staining, cells were washed with PBS-bovine serum albu-
min, and fluorescence intensity was measured on a EPICS
XL4C cytofluorometer (Coulter, Coultronics, Margency,
France). The percentage of apoptotic cells was also as-
sessed by flow cytometry analysis using the impermeant
DNA intercalant YOPRO-1 (10 mM) (EXmax/EMmax [nm]5
491/509) as described previously (Idziorek et al., 1995).
Assays for apoptosis induced by membrane-
expressed gp120
HEK 293 cells and HEK 293 cells transiently trans-
fected by a vector pBRUDgag (referred to as HEK 293/
gp120 cells) were mixed with CD41 CEM cells (at a ratio
of 3 3 106 HEK 293/gp120 cells for 1 3 106 CEM cells)
and incubated at 37°C for 2 to 3 days either in medium
alone or medium containing antibodies at saturating
concentrations for the corresponding antigen (CD4,
CD45). After incubation, the non-adherent CEM cells
were harvested. The absence of contaminating HEK 293
cells was controlled by FACS analysis using cell-surface
labelling of CD45 antigen on harvested cells (in each
experiment more than 99% cells were CEM). The per-
centage of apoptotic cells was measured by flow cytom-
etry analysis using YOPRO-1.
ACKNOWLEDGMENTS
We thank Patrice Lassus (IGMM, Montpellier) for helpful discus-
sions. We also thank Pierre Corbeau and Leigh Dawson (CRBM, Mont-
pellier) for critical reading of the manuscript. This work was supported
by Institutional funds from the Centre National de la Recherche Scien-
tifique (CNRS), the Institut National de la Sante´ et de la Recherche
Me´dicale (INSERM), a grant (to C. D.) from the Agence Nationale de
Recherches sur le SIDA (ANRS); C. G. is fellow of the ANRS.
REFERENCES
Afonson, C. L., Neilan, J. G., Kutish, G. F., and Rock, D. L. (1996). An
african swine fever virus bcl-2 homolog, 5-HL, supresses apoptotic
cell death. J. Virol. 70, 4858–4863.
Ameisen, J. C. (1994). Programmed cell death (apoptosis) and cell
survival regulation: Relevance to AIDS and cancer. AIDS 8, 1197–
1213.
Ameisen, J.-C., and Capron, A. (1991). Cell dysfunction and depletion in
AIDS: The programmed cell death hypothesis. Immunol. Today 12,
102–105.
Badley, A. D., McElhinny, J. A., Leibson, P. J., Lynch, D. H., Alderson,
M. R., and Paya, C. V. (1996). Upregulation of Fas ligand expression
by human immunodeficiency virus in human macrophages mediates
apoptosis of uninfected T lymphocytes. J. Virol. 70, 199–206.
Benkirane, M., Corbeau, P., Housset, V., and Devaux, C. (1993). An
antibody that binds the immunoglobulin CDR3-like region of the CD4
molecule inhibits provirus transcription in HIV-infected T cells. EMBO
J. 12, 4909–4921.
Benkirane, M., Hirn, M., Carrie`re, D., and Devaux, C. (1995a). Functional
epitope analysis of the human CD4 molecule: Antibodies that inhibit
human immunodeficiency virus type 1 gene expression bind to the Ig
CDR3-like region of CD4. J. Virol. 69, 6898–6903.
Benkirane, M., Jeang, K.-T., and Devaux, C. (1994). The cytoplasmic
domain of CD4 plays a critical role during the early stages of HIV
infection in T-cells. EMBO J. 13, 5559–5569.
Benkirane, M., Schmid-Antomarchi, H., Littman, D. R., Hirn, M., Rossi, B.,
and Devaux, C. (1995b). The cytoplasmic tail of the CD4 molecule is
required for inhibition of human immunodeficiency virus type 1 rep-
lication by antibodies that bind the CDR3-like region of the D1
domain of CD4. J. Virol. 69, 6904–6910.
Borvak, J., Chou, C. S., Bell, K., Van Dyke, G., Zola, H., Ramilo, O., and
261INHIBITION OF HIV-1-INDUCED APOPTOSIS
Vitetta, E. S. (1995). Expression of CD25 defines peripheral blood
mononuclear cells with productive versus latent HIV infection. J. Im-
munol. 155, 3196–3204.
Briant, L., Benkirane, M., Girard, M., Hirn, M., Iosef, C., and Devaux, C.
(1996a). Inhibition of human immunodeficiency virus type 1 produc-
tion in infected peripheral blood mononuclear cells by human leu-
kocyte antigen class I-specific antibodies: Evidence for a novel
antiviral mechanism. J. Virol. 70, 5213–5220.
Briant, L., Coudronnie`re, N., Robert-Hebmann, V., Benkirane, M., and
Devaux, C. (1996b). Binding of HIV-1 virions or gp120-anti-gp120
immune complexes to HIV-1-infected quiescent peripheral blood
mononuclear cells reveals latent infection. J. Immunol. 156, 3994–
4004.
Chiou, S.-K., Tseng, C. C., Rao, L., and White, E. (1994). Functional
complementation of the adenovirus E1B 19-kilodalton protein with
bcl-2 in the inhibition of apoptosis in infected cells. J. Virol. 68,
6553–6566.
Chirmule, N., Goonewardena, H., Pahwa, S., Pasieka, R., Kalyanaraman,
V. S., and Pahwa, S. (1995). HIV-1 envelope glycoproteins induce
activation of activated protein-1 in CD41T cells. J. Biol. Chem. 270,
19364–19369.
Corbeau, P., Benkirane, M., Weil, R., David, C., Emiliani, S., Olive, D.,
Mawas, C., Serre, A., and Devaux, C. (1993). IgCDR3-like region of the
CD4 molecule is involved in HIV-induced syncytia formation but not
in viral entry. J. Immunol. 150, 290–301.
Corbeau, P., Devaux, C., Kourilsky, F., and Chermann, J.-C. (1990). An
early post-infection signal mediated by monoclonal anti-b2 micro-
globulin antibody is responsible for delayed production of human
immunodeficiency virus type 1 in activated peripheral blood mono-
nuclear cells. J. Virol. 64, 1459–1464.
Corbeil, J., and Richman, D. D. (1995). Productive infection and subse-
quent interaction of CD4-gp120 at the cellular membrane is required
for HIV-induced apoptosis of CD41T cells. J. Gen. Virol. 76, 681–690.
Coudronnie`re, N., Corbeil, J., Robert-Hebmann, V., Mesnard, J.-M., and
Devaux, C. (1998). The lck protein tyrosine kinase is not involved in
antibody-mediated CD4 (CDR3-loop) signal transduction that inhibit
HIV-1 transcription. Eur. J. Immunol. 28, 1445–1457.
Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D. H.,
Greaves, M. F., and Weiss, R. A. (1984). The CD4 (T4) antigen is an
essential component of the receptor for the AIDS retrovirus. Nature
312, 763–767.
Gehri, R., Hahn, S., Rothen, M., Steuerwald, M., Nuesch, R., and Erb, P.
(1995). The Fas receptor in HIV infection: Expression on peripheral
blood lymphocytes and role in the depletion of T cells. AIDS 10, 9–16.
Gillet, G., Guerin, M., Trembleau, A., and Brun, G. (1995). A bcl-2-related
gene is activated in avian cells transformed by the rous sarcoma
virus. EMBO J. 14, 1372–1381.
Gougeon, M.-L., Lecoeur, H., Dulioust, A., Enouf, M.-G., Crouvoisier, M.,
Goujard, C., Debord, T., and Montagnier, L. (1996). Programmed cell
death in peripheral lymphocytes from HIV-infected persons. J. Immu-
nol. 156, 3509–3520.
Guillerm, C., Coudronnie`re, N., Robert-Hebmann, V., and Devaux, C.
(1998). Delayed human immunodeficiency virus type 1-induced apo-
ptosis in cells expressing truncated forms of CD4. J. Virol. 72, 1754–
1761.
Henderson, S., Huen, D., Rowe, M., Dawson, C., Johnson, G., and
Rickinson, A. (1993). Epstein-Barr virus-coded BHRF1 protein, a viral
homolgue of bcl-2, protects human B cells from programmed cell
death. Proc. Natl. Acad. Sci. USA 90, 8479–8483.
Hovanessian, A. G. (1994). Apoptosis in HIV infection: the role of
extracellular and transmembrane glycoproteins, p. 21–42. In ‘‘Apopto-
sis II: The Molecular Basis of Apoptosis in Disease.’’ Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, New York.
Idziorek, T., Estaquier, J., de Bels, F., and Ameisen, J.-C. (1995). YOPRO-1
permits cytofluorometric analysis of apoptosis without interfering
with cell viability. J. Immunol. Methods 185, 249–258.
Jabado, N., Le Diest, F., Fisher, A., and Hivroz, C. (1994). Interaction of
HIV gp120 and anti-CD4 antibodies with the CD4 molecule on human
CD41 T cells inhibits the binding activity of NF-AT, NF-kB, and AP-1,
three nuclear factors regulating interleukin-2 gene enhancer activity.
Eur. J. Immunol. 24, 2646–2652.
Jacotot, E., Krust, B., Callebaut, C., Laurent-Crawford, Blanco, J., and
Hovanessian, A. G. (1997). HIV-1 envelope glycoproteins-mediated
apoptosis is regulated by CD4 dependent and independent mecha-
nisms. Apoptosis 2, 47–60.
Kameoka, M., Kimura, T., Zhong, Q., Zheng, Y.-H., Luftig, R. B., and Ikuta,
K. (1996). Induction of apoptosis by protease-defective particle prep-
arations of human immunodeficiency virus type 1 is specific to a
subset of U937-derived subclones. Int. Immunol. 8, 1687–1697.
Katsikis, P. D., Wunderlich, E. S., Smith, C. A., Herzenberg, L. A., and
Herzenberg, L. A. (1995). Fas antigen stimulation induces marked
apoptosis of T lymphocytes in human immunodeficiency virus-in-
fected individuals. J. Exp. Med. 181, 2029–2036.
Klatzman, D., Barre´-Sinoussi, F., Nugeyre, M.-T., Dauget, C., Vilmer, E.,
Gricelli, C., Brun-Vezinet, F., Rouzioux, C., Gluckman, J.-C., Cherman,
J.-C., and Montagnier, L. (1984). Selective tropism of lymph adenop-
athy associated virus (LAV) for helper-inducer T lymphocytes. Sci-
ence 225, 59–63.
Laurent-Crawford, A. G., Krust, B., Muller, S., Rivie`re, Y., Rey, M.-A.,
Bechet, J.-M., Montagnier, L., and Hovanessian, A. G. (1991). The
cytopathic effect of HIV is associated with apoptosis. Virology 185,
829–839.
Laurent-Crawford, A. G., Krust, B., Rivie`re, Y., Desgranges, C., Muller, S.,
Kieny, M.-P., Dauguet, C., and Hovanessian, A. G. (1993). Membrane
expression of HIV envelope glycoproteins triggers apoptosis in CD4
cells. AIDS Res. Hum. Retroviruses 9, 761–773.
Lemasson, I., Briant, L., Hague, B., Coudronnie`re, N., He`ron, L., David,
C., Rebouissou, C., Kindt, T., and Devaux, C. (1996). An antibody that
binds domain 1 of CD4 inhibits replication of HIV-1 but not HTLV-I-
transformed cell line. J. Immunol. 156, 859–865.
Levine, B., Huang, Q., Isaacs, J. T., Reed, J. C., Griffin, D. E., and
Hardwick, J. M. (1993). Conversion of lytic to persistent alphavirus
infection by the bcl-2 cellular oncogene. Nature 361, 739–742.
Li, C. J., Friedman, D. J., Wang, C., Metelev, V., and Pardee, A. B. (1995).
Induction of apoptosis in uninfected lymphocytes by HIV-1 tat pro-
tein. Science 268, 429–431.
Maldarelli, F., Sato, H., Berthold, E., Orenstein, J., and Martin, M. A.
(1995). Rapid induction of apoptosis by cell-to-cell transmission of
human immunodeficiency virus type 1. J. Virol. 69, 6457–6465.
Merzouki, A., Patel, P., Cassol, S., Ennaji, M., Tailor, P., Turcotte, F. R.,
O’Shaughnessy, M., and Arella, M. (1995). HIV-1 gp120/160 express-
ing cells upregulate HIV-1 LTR directed gene expression in a cell line
transfected with HIV-1 LTR-reporter gene constructs. Cell Mol. Biol.
41, 445–452.
Moore, J. P., Sattentau, Q. J., Klasse, P. J., and Burkly, L. C. (1992). A
monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced
conformational changes in the envelope glycoproteins of human
immunodeficiency virus type (HIV-1) and HIV-1 infection of CD41
cells. J. Virol. 66, 4784–4793.
Pe´le´raux, A., Peyron, J.-F., and Devaux, C. (1998). Inhibition of HIV-1
replication by a monoclonal antibody directed toward the comple-
mentarity determining region 3-like domain of CD4 in CD45 express-
ing and CD45-deficient cells. Virology 242, 233–237.
Popik, W., and Pitha, P. M. (1996). Binding of human immunodeficiency
virus type 1 to CD4 induces association of Lckand Raf-1 and acti-
vates Raf-1 by a Ras-independent pathway. Mol. Cell. Biol. 16, 6532–
6541.
Purvis, S. F., Jacobberger, J. W., Sramkoski, M., Patki, A. H., and Leder-
man, M. M. (1995). HIV type 1 Tat protein inducesapoptosis and
death in Jurkat cells. AIDS Res. Hum. Retroviruses 11, 443–450.
Rosenberg, Z. F., and Fauci, A. S. (1991). Immunopathogenesis of HIV
infection. FASEB J. 5, 2382–2390.
Rudd, C. E., Trevillyan, J. M., Dasgupta, J. D., Wong, L. L., and Schloss-
man, S. F. (1988). The CD4 receptor is complexed in detergent lysates
262 GUILLERM ET AL.
to a protein-tyrosine kinase from human T lymphocytes. Proc. Natl.
Acad. Sci. USA 85, 5190–5194.
Schmid-Antomarchi, H., Benkirane, M., Breittmayer, V., Husson, H.,
Ticchioni, M., Devaux, C., and Rossi, B. (1996). HIV induces activation
of phosphatidyl inositol 4-kinase and mitogen-activated protein ki-
nase by interacting with T cell CD4 surface molecules. Eur. J. Immu-
nol. 26, 717–720.
Shen, Y., and Shenk, T. E. (1995). Viruses and apoptosis. Curr. Opin.
Gen. Dev. 5, 105–111.
Terai, C., Kornbluth, R. S., Pauza, C. D., Richman, D. D., and Carson, D. A.
(1991). Apoptosis as a mechanism of cell death in cultured T lympho-
blasts acutely infected with HIV-1. J. Clin. Invest. 87, 1710–1715.
Tuosto, L., Piazza, C., Moretti, S., Modesti, A., Greenlaw, R., Lechler, R.,
Lombardi, G., and Piccolella, E. (1995). Ligation of either CD2 or
CD28 rescues CD41 T cells from HIV-gp120-induced apoptosis. Eur.
J. Immunol. 25, 2917–2922.
Veillette, A., Bookman, M. A., Horak, E. M., Samelson, L. E., and Bolen,
J. B. (1989). Signal transduction through the CD4 receptor involves
the activation of the internal membrane tyrosine-protein kinase
p56lck. Nature 338, 257–259.
Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Khein, J.,
Walczak, H., Debatin, K.-M., and Krammer, P. H. (1995). Sensitization
of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.
Nature 372, 497–500.
Yamada, T., Yamaoka, S., Goto, T., Nakai, M., Tsujimoto, Y., and Ha-
tanaka, M. (1994). The human T-cell leukemia virus type I Tax protein
induces apoptosis which is blocked by the bcl-2 protein. J. Virol. 68,
3374–3379.
263INHIBITION OF HIV-1-INDUCED APOPTOSIS
